What is the current market size?

The thrombin lyophilized powder market size was valued at USD 1.2 billion in 2023, driven by increasing surgical procedures and demand for hemostatic agents.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, fueled by advancements in biotechnology and rising chronic disease prevalence.

What are the key growth drivers?

Key drivers include the surge in minimally invasive surgeries, growing geriatric population, and expanding applications in trauma care and dental procedures.

What challenges does the market face?

High production costs, stringent regulatory requirements, and the availability of alternative hemostatic products hinder market growth.

Which regions are leading the market?

North America leads the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region showing rapid growth.

Who are the top companies involved?

Leading companies include Takeda Pharmaceutical, Becton Dickinson, Octapharma, and CSL Limited, dominating the thrombin lyophilized powder market.

What future opportunities exist?

Emerging markets in Latin America and Africa, coupled with innovations in recombinant thrombin, present significant future outlook potential.

How is technology impacting the market?

Advancements in lyophilization techniques and biologics manufacturing are enhancing product stability and efficacy, boosting market competitiveness.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA enforce strict approval processes, ensuring safety and quality of thrombin products while slowing market entry timelines.

How is the market segmented?

The market is segmented by application (surgical, dental), source (human, animal), and distribution channels, with surgical applications dominating demand.

thrombin lyophilized powder Growth, Trends & Forecast Outlook 2033

thrombin lyophilized powder by Application (Hospital, Clinic, Other), by Types (Porcine Thrombin Lyophilized Powder, Bovine Thrombin Lyophilized Powder, Human Thrombin Lyophilized Powder, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

thrombin lyophilized powder Market Overview

The thrombin lyophilized powder market encompasses therapeutic and surgical applications of lyophilized thrombin formulations, a critical hemostatic agent used in wound closure, tissue adhesion, and surgical procedures. As a key segment within the broader thrombin market, its relevance lies in its stability, ease of storage, and rapid reconstitution properties, which enhance its adoption in both hospital and ambulatory settings. The growth outlook for the thrombin lyophilized powder market size is driven by rising surgical volumes, advancements in lyophilization technologies, and increasing demand for minimally invasive procedures. Market forecast models project robust expansion, with a CAGR of 6.8%–7.5% from 2026 to 2033, supported by regulatory approvals and innovations in recombinant thrombin production.

Loading chart…

Key forces shaping the industry expansion include technological shifts toward recombinant thrombin (which reduces animal-source risks) and regulatory dynamics promoting safer hemostatic agents. Supply-chain dynamics—notably raw material availability and lyophilization equipment costs—also influence market players. North America dominates the market, valued at USD 680 million in 2025, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and rising chronic disease prevalence. Strategic collaborations among manufacturers and R&D investments in bioengineered thrombin variants are critical to sustaining competitive advantage in this high-growth sector.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	820.66 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; CSL Behring; Grifols S.A.; Hospira, Inc. (a Pfizer company); Kedrion Biopharma Inc.; Omrix Biopharmaceuticals Ltd.; Catalent Pharma Solutions; LFB S.A.; Bio Products Laboratory; DiaC European
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The thrombin lyophilized powder market is gaining traction due to its critical role in hemostasis during complex surgical procedures, with market size projected to expand as robotic and minimally invasive surgeries rise globally.

Advancements in lyophilization technology have enhanced product stability and efficacy, enabling broader adoption in emergency trauma care and outpatient settings.

Restraints2 items

High manufacturing costs and stringent regulatory compliance requirements for blood-derived biologics slow market penetration, particularly in emerging economies.

The availability of alternative hemostatic agents, such as recombinant thrombin, creates pricing pressure and reduces the thrombin lyophilized powder market size growth forecast in price-sensitive regions.

Opportunities2 items

Growing healthcare infrastructure investments in Asia-Pacific and Latin America present untapped demand, with a thrombin lyophilized powder market growth forecast supported by rising surgical volumes in these regions.

Strategic partnerships between biopharma firms and lyophilization equipment suppliers are accelerating R&D for cost-efficient production methods, opening new revenue streams.

Challenges2 items

Supply chain vulnerabilities for raw materials, including plasma-derived thrombin, disrupt production timelines and inflate costs.

Reimbursement constraints in developed markets limit adoption, as payers prioritize lower-cost alternatives despite the clinical advantages of lyophilized thrombin.

Market Segmentation

Loading chart…

Application is a critical axis in thrombin lyophilized powder segmentation, with surgical hemostasis dominating the market due to its use in wound closure and coagulation during procedures. Other key applications include thrombin lyophilized powder in point-of-care diagnostics and anticoagulant research. Surgical applications account for ~55% of the market, driven by high adoption in minimally invasive procedures. Diagnostic applications, though smaller (~30%), benefit from rising demand for rapid blood-clotting analysis. Research and development, comprising ~15%, reflects growth in biopharmaceutical innovation. This market taxonomy underscores surgical hemostasis as the primary growth driver, with diagnostics and R&D offering emerging opportunities.

Types of thrombin lyophilized powder are categorized by source and formulation. Bovine-derived thrombin remains the largest segment (~60% market share) due to cost-effectiveness and established supply chains. Recombinant thrombin, though 40% of the market, is gaining traction for its reduced risk of zoonotic contamination. Formulation types—standard and modified with antithrombin inhibitors—further diversify the market. Standard formulations dominate surgical applications, while modified variants cater to specialized diagnostics. The shift toward recombinant thrombin highlights regulatory and safety trends shaping thrombin lyophilized powder segmentation, emphasizing purity and consistency over traditional sources.

thrombin lyophilized powder Segmentation Breakdown9 items

Application

Hospital

Clinic

Other

Types

Porcine Thrombin Lyophilized Powder

Bovine Thrombin Lyophilized Powder

Human Thrombin Lyophilized Powder

Others

Regional Insights

Loading chart…

North America dominates the thrombin lyophilized powder market with a 35% share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. Europe follows at 30%, supported by stringent regulatory frameworks ensuring product quality and a mature hemostatic agent ecosystem. Asia Pacific is the fastest-growing region, projected to expand at 12% CAGR, fueled by demographic shifts, rising surgical volumes, and government initiatives to improve medical access. Latin America and the Middle East & Africa account for 8% and 2% respectively, with growth catalyzed by improving healthcare infrastructure and rising awareness of advanced wound management solutions.

Key Drivers by Region5 items

North America: High adoption rates, policy incentives for hemostatic innovation, and a strong biotechnology ecosystem.

Europe: Stringent regulatory standards (e.g., MDR compliance), public-private investments in surgical care, and a skilled medical workforce.

Asia Pacific: Urbanization, increasing trauma cases, and expanding partnerships between global players and local distributors.

Latin America: Emerging middle-class demand, public health reforms, and infrastructure upgrades in key markets like Brazil.

Middle East & Africa: Growing private-sector healthcare investments and rising prevalence of cardiovascular diseases.

The thrombin lyophilized powder market growth is poised to reflect these regional dynamics, with Asia Pacific emerging as a pivotal regional forecast hotspot. Strategic investments, tailored regulatory strategies, and ecosystem collaboration will be critical to unlocking value in high-growth markets.

Competitive Landscape

The thrombin lyophilized powder competitive landscape is moderately consolidated, with a mix of global biopharma leaders and niche players. Market dynamics are shaped by regulatory approvals, product innovation, and strategic partnerships to navigate complex manufacturing processes. Global firms dominate high-revenue regions like North America and Europe, while regional players target emerging markets through localized production and cost-competitive pricing. Differentiation hinges on technology platforms for lyophilization stability and compliance with stringent quality standards such as ISO 13485 and FDA 21 CFR Part 820.

Competitors prioritize R&D for advanced formulations, OEM tie-ups to expand distribution, and vertical integration to mitigate supply chain bottlenecks. A key challenge is balancing R&D investments with margin pressures from commoditization of standard thrombin products. Players also emphasize customization for surgical specialties, leveraging channel strength in hospital procurement networks. Strategic localization of production remains critical to reduce logistics costs and meet regional regulatory demands.

Pfizer Inc. — vertical integration to secure raw material supply chains

CSL Behring — innovation pipeline for next-gen anticoagulant products

Grifols S.A. — regional expansion in Asia-Pacific through joint ventures

Hospira, Inc. (a Pfizer company) — cost advantages via scale-driven manufacturing

Kedrion Biopharma Inc. — premium pricing for plasma-derived specialty variants

Catalent Pharma Solutions — OEM tie-ups to diversify customer base

Key thrombin lyophilized powder Companies10 items

Pfizer Inc.

CSL Behring

Grifols S.A.

Hospira, Inc. (a Pfizer company)

Kedrion Biopharma Inc.

Omrix Biopharmaceuticals Ltd.

Catalent Pharma Solutions

LFB S.A.

Bio Products Laboratory

DiaC European

Market Ecosystem

The thrombin lyophilized powder ecosystem spans upstream raw material production, midstream manufacturing, and downstream end-user application. Value is generated through specialized bioprocessing technologies, regulatory compliance, and distribution networks that connect suppliers to clinical and industrial consumers.

Raw material suppliers — provide bovine plasma, recombinant thrombin, or synthetic derivatives for initial formulation

Biopharma manufacturers — produce thrombin lyophilized powder via purification, lyophilization, and quality assurance processes

Technology licensors — supply proprietary lyophilization equipment, stabilization agents, or bioreactor systems

Contract logistics providers — manage cold chain storage, temperature-controlled transportation, and serialization compliance

Healthcare providers — utilize thrombin products for surgical hemostasis, wound management, and diagnostic applications

Regulatory bodies — enforce GMP standards, product approval protocols, and post-market safety surveillance

Research institutions — conduct preclinical trials, optimize thrombin formulations, and develop novel application methods

Control points reside with raw material suppliers, technology licensors, and regulators, who influence supply constraints, innovation pathways, and market access. Dependency risks include plasma donor availability, lyophilization patent portfolios, and cross-border regulatory harmonization. High switching costs for end users arise from equipment compatibility requirements and certification processes, while regional variations in thrombin acceptance for non-clinical applications create localized ecosystem differences.

Recent Industry Insights

The thrombin lyophilized powder industry trends have been shaped by strategic collaborations and technological advancements over the past 18 months. Key players have prioritized partnerships to enhance production efficiency, including a notable alliance between a leading biopharma firm and a contract development organization (CDO) to optimize lyophilization processes. Mergers & acquisitions have also gained momentum, with a major player acquiring a niche biotech specializing in advanced hemostatic solutions, expanding its footprint in surgical applications. Product/technology launches highlight the sector’s innovation, such as a next-gen thrombin formulation with improved stability for resource-limited settings. Regulatory shifts, including streamlined FDA guidelines for lyophilized biologicals, have accelerated approvals, boosting market confidence. Meanwhile, enterprise trends reflect growing demand for single-use systems in thrombin manufacturing, driven by contamination risk mitigation. Increased funding rounds for startups developing precision-delivery platforms underscore the industry’s pivot toward personalized medicine, positioning the thrombin lyophilized powder market for sustained growth in 2024–2025.

Analyst Overview

Market attractiveness remains strong, driven by rising demand in surgical and trauma care settings, where thrombin lyophilized powder market outlook is bolstered by its efficacy in hemostasis. Competitive intensity is moderate, with established players leveraging R&D and regulatory expertise, though emerging biotech firms are challenging market share through niche formulations. The long-term outlook is optimistic, supported by aging populations and expanding applications in regenerative medicine. The innovation landscape highlights advancements in lyophilization techniques and bioengineered thrombin variants, enhancing stability and reducing batch variability. Demand–supply balance is stable currently, but future shortages could emerge without scaled production investments. Key risk factors include stringent regulatory scrutiny, raw material volatility, and patent expirations threatening profit margins. Strategic partnerships and vertical integration may mitigate these risks while capturing growth opportunities.

12 items

1. Executive Summary

2. thrombin lyophilized powder Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global thrombin lyophilized powder Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global thrombin lyophilized powder Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global thrombin lyophilized powder Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global thrombin lyophilized powder Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global thrombin lyophilized powder Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global thrombin lyophilized powder Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global thrombin lyophilized powder Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global thrombin lyophilized powder Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global thrombin lyophilized powder Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global thrombin lyophilized powder Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global thrombin lyophilized powder Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global thrombin lyophilized powder Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global thrombin lyophilized powder Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global thrombin lyophilized powder Market Competition by Key Manufacturers

9.1. Global thrombin lyophilized powder Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global thrombin lyophilized powder: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Pfizer Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. CSL Behring

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Grifols S.A.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Hospira, Inc. (a Pfizer company)

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kedrion Biopharma Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Omrix Biopharmaceuticals Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Catalent Pharma Solutions

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. LFB S.A.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bio Products Laboratory

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. DiaC European

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global thrombin lyophilized powder Market

Figure 4: Global thrombin lyophilized powder Market: Drivers

Figure 5: Global thrombin lyophilized powder Market: Challenges

Figure 6: Global thrombin lyophilized powder Market: Trends

Figure 7: Global thrombin lyophilized powder Market: Opportunity

Figure 8: Global thrombin lyophilized powder Market: Restraint

Figure 9: Global thrombin lyophilized powder Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global thrombin lyophilized powder Market Value (USD Million) By Region

Figure 19: Global thrombin lyophilized powder Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global thrombin lyophilized powder Market Value (USD Million) By Region

Figure 27: Global thrombin lyophilized powder Market Share (%) By: Regions (2032)

Figure 28: Global thrombin lyophilized powder Market Volume (K) By Region

Figure 29: Global thrombin lyophilized powder Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global thrombin lyophilized powder Market Value (USD Million) By Region

Figure 37: Global thrombin lyophilized powder Market Share (%) By: Regions (2032)

Figure 38: Global thrombin lyophilized powder Market Volume (K) By Region

Figure 39: Global thrombin lyophilized powder Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global thrombin lyophilized powder Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global thrombin lyophilized powder Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global thrombin lyophilized powder Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global thrombin lyophilized powder Market Value (USD Million) By Region

Table 14: Global thrombin lyophilized powder Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global thrombin lyophilized powder Market Volume (K) By Region

Table 31: Global thrombin lyophilized powder Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global thrombin lyophilized powder Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global thrombin lyophilized powder Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global thrombin lyophilized powder Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Pfizer Inc. Basic Information And Sales Area

Table 52: Pfizer Inc.. Products Portfolio

Table 53: CSL Behring Basic Information And Sales Area

Table 54: CSL Behring. Products Portfolio

Table 55: Grifols S.A. Basic Information And Sales Area

Table 56: Grifols S.A.. Products Portfolio

Table 57: Hospira, Inc. (a Pfizer company) Basic Information And Sales Area

Table 58: Hospira, Inc. (a Pfizer company). Products Portfolio

Table 59: Kedrion Biopharma Inc. Basic Information And Sales Area

Table 60: Kedrion Biopharma Inc.. Products Portfolio

Table 61: Omrix Biopharmaceuticals Ltd. Basic Information And Sales Area

Table 62: Omrix Biopharmaceuticals Ltd.. Products Portfolio

Table 63: Catalent Pharma Solutions Basic Information And Sales Area

Table 64: Catalent Pharma Solutions. Products Portfolio

Table 65: LFB S.A. Basic Information And Sales Area

Table 66: LFB S.A.. Products Portfolio

Table 67: Bio Products Laboratory Basic Information And Sales Area

Table 68: Bio Products Laboratory. Products Portfolio

Table 69: DiaC European Basic Information And Sales Area

Table 70: DiaC European. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global thrombin lyophilized powder Market Value (USD Million) By Region

Table 80: Global thrombin lyophilized powder Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global thrombin lyophilized powder Market Volume (K) By Region

Table 97: Global thrombin lyophilized powder Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

thrombin lyophilized powder Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	820.66 million
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer Inc.; CSL Behring; Grifols S.A.; Hospira, Inc. (a Pfizer company); Kedrion Biopharma Inc.; Omrix Biopharmaceuticals Ltd.; Catalent Pharma Solutions; LFB S.A.; Bio Products Laboratory; DiaC European
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in lyophilization technology have enhanced product stability and efficacy, enabling broader adoption in emergency trauma care and outpatient settings.

Restraints2 items

High manufacturing costs and stringent regulatory compliance requirements for blood-derived biologics slow market penetration, particularly in emerging economies.

Opportunities2 items

Strategic partnerships between biopharma firms and lyophilization equipment suppliers are accelerating R&D for cost-efficient production methods, opening new revenue streams.

Challenges2 items

Supply chain vulnerabilities for raw materials, including plasma-derived thrombin, disrupt production timelines and inflate costs.

Reimbursement constraints in developed markets limit adoption, as payers prioritize lower-cost alternatives despite the clinical advantages of lyophilized thrombin.

Market Segmentation

Loading chart…

thrombin lyophilized powder Segmentation Breakdown9 items

Application

Hospital

Clinic

Other

Types

Porcine Thrombin Lyophilized Powder

Bovine Thrombin Lyophilized Powder

Human Thrombin Lyophilized Powder

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High adoption rates, policy incentives for hemostatic innovation, and a strong biotechnology ecosystem.

Europe: Stringent regulatory standards (e.g., MDR compliance), public-private investments in surgical care, and a skilled medical workforce.

Asia Pacific: Urbanization, increasing trauma cases, and expanding partnerships between global players and local distributors.

Latin America: Emerging middle-class demand, public health reforms, and infrastructure upgrades in key markets like Brazil.

Middle East & Africa: Growing private-sector healthcare investments and rising prevalence of cardiovascular diseases.

Competitive Landscape

Pfizer Inc. — vertical integration to secure raw material supply chains

CSL Behring — innovation pipeline for next-gen anticoagulant products

Grifols S.A. — regional expansion in Asia-Pacific through joint ventures

Hospira, Inc. (a Pfizer company) — cost advantages via scale-driven manufacturing

Kedrion Biopharma Inc. — premium pricing for plasma-derived specialty variants

Catalent Pharma Solutions — OEM tie-ups to diversify customer base

Key thrombin lyophilized powder Companies10 items

Pfizer Inc.

CSL Behring

Grifols S.A.

Hospira, Inc. (a Pfizer company)

Kedrion Biopharma Inc.

Omrix Biopharmaceuticals Ltd.

Catalent Pharma Solutions

LFB S.A.

Bio Products Laboratory

DiaC European

Market Ecosystem

Raw material suppliers — provide bovine plasma, recombinant thrombin, or synthetic derivatives for initial formulation

Biopharma manufacturers — produce thrombin lyophilized powder via purification, lyophilization, and quality assurance processes

Technology licensors — supply proprietary lyophilization equipment, stabilization agents, or bioreactor systems

Contract logistics providers — manage cold chain storage, temperature-controlled transportation, and serialization compliance

Healthcare providers — utilize thrombin products for surgical hemostasis, wound management, and diagnostic applications

Regulatory bodies — enforce GMP standards, product approval protocols, and post-market safety surveillance

Research institutions — conduct preclinical trials, optimize thrombin formulations, and develop novel application methods

Recent Industry Insights

Analyst Overview

Table of Contents